Abstract
Chemotherapy remains the mainstay of metastatic triple negative breast cancer treatment; however, angiogenesis and epidermal growth factor receptor are potential targets. The present phase II clinical trial of nab-paclitaxel and bevacizumab, followed by maintenance therapy with bevacizumab and erlotinib, demonstrated progression-free survival similar to that with other regimens. Most patients experienced a partial response and received maintenance therapy, resulting in a significant break from cytotoxic chemotherapy.
| Original language | English (US) |
|---|---|
| Journal | Clinical Breast Cancer |
| DOIs | |
| State | Published - Jan 1 2019 |
Keywords
- Circulating endothelial cells
- Circulating tumor cells
- Erlotinib
- Metastatic
- Nab-paclitaxel bevacizumab
- Triple negative breast cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib'. Together they form a unique fingerprint.
Cite this
Seattle Cancer Care Alliance Network Investigators (2019). Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2018.12.008